America and Britain Forge Duty-Free Arrangement on Drugs.

Britain and America have agreed to a major trade agreement that will keep no duties on UK medicine exports being sold in the American market.

The Terms of the Pact

Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This move ensures that import taxes on these crucial exports will be held at nothing for a timeframe of the next three years.

This deal follows recent warnings to dramatically increase tariffs on patented drug products, with figures floated as high as 100%.

"This agreement between the United Kingdom bolsters the global environment for innovative medicines and brings much-needed balance to transatlantic drug exports," an announcement noted.

Trade Significance

Medicines represent one of the UK's largest exports to the America, which is easily the largest destination for major companies like GSK and AstraZeneca.

Statistics show that in the year to the end of the third quarter, the UK exported pharmaceutical products totaling billions to the US. This value accounted for nearly one-fifth of all goods exports in that period.

"This deal safeguards jobs, stimulates investment and facilitates the UK to emerge as a worldwide center for medical research," a minister commented.

Specific UK Commitments

The pact involves several key pledges from the UK:

• Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
• Higher Drug Budget: There is a goal to increase total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
• Rebate Cap: The amount manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, repayments topped 20%.

Broader Context

This agreement follows a protracted tension between the drug companies and the British authorities over drug pricing and approval rates.

This friction were intensified by arguments that US consumers were paying significantly more for the identical medicines than consumers in the other developed nations.

Recently, several major manufacturing plans in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.

The Science Minister publicly accepted that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its resources over the past decade.